ABOUT US

Global Leader of Cancer Treatments

History

img of buillding
  • 2019
    Oct.

    Investment agreement with Aju Pharm & KODIT

    Sep.

    Expansion & new location of Pankyo R&D center

    Jun.

    ATB-101, “K-Startup” R&D funding by Government (Ministry of SMEs and Startups)

    Licensed-in K284-6111, the new generation oncology targeted therapy candidate

    May.

    TGF-β2 Targeting ASO CMO agreement with ST Pharm

    Apr.

    ATB-301 selected in “Pharm Navi” project by MFDS (such as “Fast Track” regulation system in US FDA)

    Jan.

    ATB-101 Tech Transfer and Investment agreement with Jeil Pharm.

  • 2018
    Sep.

    Pankyo R&D center Establishment

    Aug.

    Angel Investment

    Jul.

    Investment agreement with TIPS

    Feb.

    Venture designation (Korea Technology Finance Corporation)

    Jan.

    Company name change to Autotelic Bio

  • 2017
    Sep.

    ATB-101 Government R&D grant(Ministry of SMEs and Startups)

    Corporate R&D center accreditation

  • 2015
    Nov.

    Autotelic Korea Establishment (Foreign investment company)